HIGHLIGHTS
- who: Najmeh Kaffash Farkhad from the Department of Immunology, Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran have published the paper: Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial, in the Journal: (JOURNAL)
- what: Based on these trials and available information, in this study the authors aim to evaluate the safety of 3 doses injection of UC-MSCs in COVID-19-induced ARDS patients. ILu201110 levels Cytokine IL-10 at the beginning of the study showed an insignificant difference . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.